197 related articles for article (PubMed ID: 16119180)
21. Quality of Life Evaluation in Saudi Arabian Pediatric Patients with Primary Immunodeficiency Diseases Receiving 20% Subcutaneous IgG Infusions at Home.
Al-Saud B; AlRumayyan N; Alfattani A; Awwad SA; Al Saud D; Mohammed R; Albuhairi S; Elshorbagi S; Balhareth SS; Al-Dhekri H; Arnaout R; De Vol EB; Al-Mousa H
J Clin Immunol; 2023 Aug; 43(6):1360-1366. PubMed ID: 37145392
[TBL] [Abstract][Full Text] [Related]
22. Immunoglobulin Replacement Therapy for Primary Immunodeficiency.
Sriaroon P; Ballow M
Immunol Allergy Clin North Am; 2015 Nov; 35(4):713-30. PubMed ID: 26454315
[TBL] [Abstract][Full Text] [Related]
23. [Subcutaneous immunoglobulin substitution and therapy].
Gulácsy V; Maródi L
Orv Hetil; 2011 Jan; 152(2):64-7. PubMed ID: 21177233
[TBL] [Abstract][Full Text] [Related]
24. 20% subcutaneous immunoglobulin for patients with primary immunodeficiency diseases: A systematic review.
Song J; Zhang L; Li Y; Quan S; Liang Y; Zeng L; Liu Y
Int Immunopharmacol; 2015 Apr; 25(2):457-64. PubMed ID: 25633961
[TBL] [Abstract][Full Text] [Related]
25. Evaluating dose ratio of subcutaneous to intravenous immunoglobulin therapy among patients with primary immunodeficiency disease switching to 20% subcutaneous immunoglobulin therapy.
Krishnarajah G; Lehmann JK; Ellman B; Bhak RH; DerSarkissian M; Leader D; Bullinger AL; Sheng Duh M
Am J Manag Care; 2016 Oct; 22(15 Suppl):s475-s481. PubMed ID: 27849353
[TBL] [Abstract][Full Text] [Related]
26. Quality of life and health-care resource utilization among children with primary immunodeficiency receiving home treatment with subcutaneous human immunoglobulin.
Fasth A; Nyström J
J Clin Immunol; 2008 Jul; 28(4):370-8. PubMed ID: 18256911
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and tolerability of 16% subcutaneous immunoglobulin compared with 20% subcutaneous immunoglobulin in primary antibody deficiency.
Niebur HB; Duff CM; Shear GF; Nguyen D; Alberdi TK; Dorsey MJ; Sleasman JW
Clin Exp Immunol; 2015 Sep; 181(3):441-50. PubMed ID: 25761372
[TBL] [Abstract][Full Text] [Related]
28. Facilitated subcutaneous immunoglobulin (fSCIg) therapy--practical considerations.
Ponsford M; Carne E; Kingdon C; Joyce C; Price C; Williams C; El-Shanawany T; Williams P; Jolles S
Clin Exp Immunol; 2015 Dec; 182(3):302-13. PubMed ID: 26288095
[TBL] [Abstract][Full Text] [Related]
29. [Replacement therapy with subcutaneous immunoglobulin in primary immunodeficiency in children].
Pac M
Pol Merkur Lekarski; 2011 Jun; 30(180):413-6. PubMed ID: 21751550
[TBL] [Abstract][Full Text] [Related]
30. Economic evaluation of immunoglobulin replacement in patients with primary antibody deficiencies.
Beauté J; Levy P; Millet V; Debré M; Dudoit Y; Le Mignot L; Tajahmady A; Thomas C; Suarez F; Pellier I; Hermine O; Aladjidi N; Mahlaoui N; Fischer A;
Clin Exp Immunol; 2010 May; 160(2):240-5. PubMed ID: 20041884
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of home-based subcutaneous immunoglobulin G in elderly patients with primary immunodeficiency diseases.
Stein MR; Koterba A; Rodden L; Berger M
Postgrad Med; 2011 Sep; 123(5):186-93. PubMed ID: 21904101
[TBL] [Abstract][Full Text] [Related]
32. Preliminary evidence on the measurement properties of the Chinese version of the Child Health Questionnaire, parent form (CHQ-pF50) and child form (CHQ-CF87).
Ng JY; Landgraf JM; Chiu CS; Cheng NL; Cheung YF
Qual Life Res; 2005 Sep; 14(7):1775-81. PubMed ID: 16119188
[TBL] [Abstract][Full Text] [Related]
33. The use of the SF-36 questionnaire in adult survivors of childhood cancer: evaluation of data quality, score reliability, and scaling assumptions.
Reulen RC; Zeegers MP; Jenkinson C; Lancashire ER; Winter DL; Jenney ME; Hawkins MM
Health Qual Life Outcomes; 2006 Oct; 4():77. PubMed ID: 17022814
[TBL] [Abstract][Full Text] [Related]
34. Subcutaneous Immunoglobulin Therapy in the Chronic Management of Myasthenia Gravis: A Retrospective Cohort Study.
Bourque PR; Pringle CE; Cameron W; Cowan J; Chardon JW
PLoS One; 2016; 11(8):e0159993. PubMed ID: 27490101
[TBL] [Abstract][Full Text] [Related]
35. Switching Patients to Home-Based Subcutaneous Immunoglobulin: an Economic Evaluation of an Interprofessional Drug Therapy Management Program.
Perraudin C; Bourdin A; Spertini F; Berger J; Bugnon O
J Clin Immunol; 2016 Jul; 36(5):502-10. PubMed ID: 27139500
[TBL] [Abstract][Full Text] [Related]
36. A new instrument for measuring anticoagulation-related quality of life: development and preliminary validation.
Samsa G; Matchar DB; Dolor RJ; Wiklund I; Hedner E; Wygant G; Hauch O; Marple CB; Edwards R
Health Qual Life Outcomes; 2004 May; 2():22. PubMed ID: 15132746
[TBL] [Abstract][Full Text] [Related]
37. The reliability, validity, and preliminary responsiveness of the Eye Allergy Patient Impact Questionnaire (EAPIQ).
Alexander M; Berger W; Buchholz P; Walt J; Burk C; Lee J; Arbuckle R; Abetz L
Health Qual Life Outcomes; 2005 Oct; 3():67. PubMed ID: 16259630
[TBL] [Abstract][Full Text] [Related]
38. Home-based subcutaneous immunoglobulin therapy vs hospital-based intravenous immunoglobulin therapy: A prospective economic analysis.
Fu LW; Song C; Isaranuwatchai W; Betschel S
Ann Allergy Asthma Immunol; 2018 Feb; 120(2):195-199. PubMed ID: 29413344
[TBL] [Abstract][Full Text] [Related]
39. Cost-utility analysis comparing hospital-based intravenous immunoglobulin with home-based subcutaneous immunoglobulin in patients with secondary immunodeficiency.
Windegger TM; Nghiem S; Nguyen KH; Fung YL; Scuffham PA
Vox Sang; 2019 Apr; 114(3):237-246. PubMed ID: 30883804
[TBL] [Abstract][Full Text] [Related]
40. Psychometric validation of the child health questionnaire (CHQ) in a sample of children and adolescents with attention-deficit/hyperactivity disorder.
Rentz AM; Matza LS; Secnik K; Swensen A; Revicki DA
Qual Life Res; 2005 Apr; 14(3):719-34. PubMed ID: 16022065
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
